Optum

Expert

ICD-10-CM Expert for Hospitals

The complete official guidelines and code set

Codes valid from October 1, 2025
through September 30, 2026

2026

optumcoding.com

Contents

A **Adult Age: 15-124**

These diagnoses are intended for patients between the age of 15 and 124 years.

R54 Age-related physical debility A
Frailty
Old age
Senescence
Senile asthenia
Senile debility
EXCLUDES 1 *age-related cognitive decline (R41.81)*
sarcopenia (M62.84)
senile psychosis (FØ3.-)
senility NOS (R41.81)

Sex Edits

Effective October 1, 2024, the Medicare Code Editor (MCE), a program used to detect and report errors in coding claims data, has deactivated the sex conflict edit. There is no longer a female or male edit restriction for ICD-10-CM codes.

H1-H14 **Hospital Acquired Condition (HAC)**

These icons identify codes that are high-cost and/or high-volume (CC or MCC), that when assigned as a secondary diagnosis result in assignment of a case to a higher-paying MS-DRG. The condition or diagnosis represented by these codes is considered reasonably preventable through the application of evidence-based guidelines. If the condition is not present on admission (meaning it developed during the hospital admission), the case will not group to the higher-paying MS-DRG based solely upon the reporting of the HAC code. Many of these HACs are conditional and are based on reporting the specific diagnosis code(s) in combination with certain procedure codes.

A comprehensive list of all HAC codes that coincide with these icons appears in appendix G, at the back of this book.

Note: Hospital-acquired conditions do not impact MS-LTC-DRG assignment.

N15.1 Renal and perinephric abscess MCC H6

CC **CC Condition**

This icon identifies a complication or comorbidity diagnosis that may affect DRG assignment. A complication or comorbidity diagnosis, CC condition, is defined as a significant acute disease, a significant acute manifestation of a chronic disease, an advanced or end-stage chronic disease, or a chronic disease associated with systemic physiological decompensation and debility that have consistently greater impact on hospital resources.

A comprehensive list of ICD-10-CM codes considered a CC appears in appendix E, at the back of this book.

G9Ø.59 Complex regional pain syndrome I of other specified site CC

MCC **MCC Condition**

This icon identifies a major complication or comorbidity diagnosis that may affect DRG assignment. An MCC condition meets the same criteria as a CC condition but is associated with a higher acuity level and hospital resource consumption is expected to be higher than that for a CC condition. There are fewer conditions that meet the criteria as an MCC than those for a CC condition.

A comprehensive list of ICD-10-CM codes considered an MCC appears in appendix D, at the back of this book.

JØ4.11 Acute tracheitis with obstruction MCC

Note: The assignment of an MS-DRG or MS-LTC-DRG often depends on the presence or absence of a secondary diagnosis code that is designated as an MCC or CC. However, in some instances the MCC or CC designation for that secondary diagnosis code is negated due to its relationship with the principal diagnosis; this is referred to as CC exclusion. The ICD-10 MS-DRG Definitions Manual included with the IPPS final rule provides a list of all principal diagnosis codes that would render ineffective the MCC/CC designation for a particular ICD-10-CM code when used as a secondary diagnosis. Optum has provided this CC exclusion list in an easily searchable data file, which can be accessed at the following:

https://www.optumcoding.com/ProductUpdates/
Title: "2025 ICD-10-CM for Hospitals CC Excludes Data File"
Password: HOSPITAL25

UNS **Unspecified Site**

This icon identifies codes that are considered an MCC or CC but lack specificity in regard to their anatomical location. The medical record documentation should be reviewed carefully, to ensure that no other code within the same category or subcategory can be assigned for greater specificity.

G81.ØØ Flaccid hemiplegia affecting unspecified side CC UNS HCC

UPD **Unacceptable Principal Diagnosis**

This icon identifies codes that should not be assigned as principal diagnosis for *inpatient* admissions. Codes with an unacceptable principal diagnosis edit are considered supplementary — describing circumstances that influence an individual's health status or an additional code — identifying conditions that are not specific manifestations but may be due to an underlying cause.

✓7th **T48.5X5 Adverse effect of other anti-common-cold drugs** UPD PE

HIV **HIV-related Condition**

This icon identifies codes that are considered a major HIV-related diagnosis. When the condition is coded in combination with a diagnosis of human immunodeficiency virus (HIV), code B2Ø, the case will move from MS-DRG/MS-LTC-DRG 977 to MS-DRGs/MS-LTC-DRGs 974-976.

G96.9 Disorder of central nervous system, unspecified HIV

PE **Present on Admission Exempt**

This icon identifies codes that do not require a present on admission (POA) indicator. These codes are considered exempt because they do not represent a current disease or injury or describe conditions that are always present on admission

B9Ø.1 Sequelae of genitourinary tuberculosis PE

HCC **CMS-HCC Condition**

This icon identifies codes that are included in the CMS-HCC risk-adjustment model.

P29.Ø Neonatal cardiac failure HCC
Code also associated underlying condition

Color Bars

Manifestation Code

Codes defined as manifestation codes appear in italic type, with a blue color bar over the code description. A manifestation cannot be reported as a first-listed code; it is sequenced as a secondary diagnosis with the underlying disease code listed first.

G32.89 Other specified degenerative disorders of nervous system in diseases classified elsewhere
Degenerative encephalopathy in diseases classified elsewhere

A

	Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior
Neoplasm, neoplastic — *continued*						
brain — *continued*						
basal ganglia	C71.0	C79.31	—	D33.0	D43.0	D49.6
cerebellopontine angle	C71.6	C79.31	—	D33.1	D43.1	D49.6
cerebellum NOS	C71.6	C79.31	—	D33.1	D43.1	D49.6
cerebrum	C71.0	C79.31	—	D33.0	D43.0	D49.6
choroid plexus	C71.7	C79.31	—	D33.1	D43.1	D49.6
corpus callosum	C71.8	C79.31	—	D33.2	D43.2	D49.6
corpus striatum	C71.0	C79.31	—	D33.0	D43.0	D49.6
cortex (cerebral)	C71.0	C79.31	—	D33.0	D43.0	D49.6
frontal lobe	C71.1	C79.31	—	D33.0	D43.0	D49.6
globus pallidus	C71.0	C79.31	—	D33.0	D43.0	D49.6
hippocampus	C71.2	C79.31	—	D33.0	D43.0	D49.6
hypothalamus	C71.0	C79.31	—	D33.0	D43.0	D49.6
internal capsule	C71.0	C79.31	—	D33.0	D43.0	D49.6
medulla oblongata	C71.7	C79.31	—	D33.1	D43.1	D49.6
meninges	C70.0	C79.32	—	D32.0	D42.0	D49.7
midbrain	C71.7	C79.31	—	D33.1	D43.1	D49.6
occipital lobe	C71.4	C79.31	—	D33.0	D43.0	D49.6
overlapping lesion	C71.8	C79.31	—	—	—	—
parietal lobe	C71.3	C79.31	—	D33.0	D43.0	D49.6
peduncle	C71.7	C79.31	—	D33.1	D43.1	D49.6
pons	C71.7	C79.31	—	D33.1	D43.1	D49.6
stem	C71.7	C79.31	—	D33.1	D43.1	D49.6
tapetum	C71.8	C79.31	—	D33.2	D43.2	D49.6
temporal lobe	C71.2	C79.31	—	D33.0	D43.0	D49.6
thalamus	C71.0	C79.31	—	D33.0	D43.0	D49.6
uncus	C71.2	C79.31	—	D33.0	D43.0	D49.6
ventricle (floor)	C71.5	C79.31	—	D33.0	D43.0	D49.6
fourth	C71.7	C79.31	—	D33.1	D43.1	D49.6
branchial (cleft) (cyst) (vestiges)	C10.4	C79.89	D00.08	D10.5	D37.05	D49.0
breast (connective tissue) (glandular tissue) (soft parts)	C50.9-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
areola	C50.0-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
axillary tail	C50.6-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
central portion	C50.1-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
inner	C50.8-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
lower	C50.8-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
lower-inner quadrant	C50.3-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
lower-outer quadrant	C50.5-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
mastectomy site (skin) — *see also* Neoplasm, breast, skin	C44.501	C79.2	—	—	—	—
specified as breast tissue	C50.8-☑	C79.81	—	—	—	—
midline	C50.8-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
nipple	C50.0-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
outer	C50.8-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
overlapping lesion	C50.8-☑	—	—	—	—	—
skin	C44.501	C79.2	D04.5	D23.5	D48.5	D49.2
basal cell carcinoma	C44.511	—	—	—	—	—
specified type NEC	C44.591	—	—	—	—	—
squamous cell carcinoma	C44.521	—	—	—	—	—
tail (axillary)	C50.6-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
upper	C50.8-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
upper-inner quadrant	C50.2-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
upper-outer quadrant	C50.4-☑	C79.81	D05.-☑	D24.-☑	D48.6-☑	D49.3
broad ligament	C57.1-☑	C79.82	D07.39	D28.2	D39.8	D49.59
bronchiogenic, bronchogenic (lung)	C34.9-☑	C78.0-☑	D02.2-☑	D14.3-☑	D38.1	D49.1
bronchiole	C34.9-☑	C78.0-☑	D02.2-☑	D14.3-☑	D38.1	D49.1
bronchus	C34.9-☑	C78.0-☑	D02.2-☑	D14.3-☑	D38.1	D49.1
carina	C34.0-☑	C78.0-☑	D02.2-☑	D14.3-☑	D38.1	D49.1
lower lobe of lung	C34.3-☑	C78.0-☑	D02.2-☑	D14.3-☑	D38.1	D49.1
main	C34.0-☑	C78.0-☑	D02.2-☑	D14.3-☑	D38.1	D49.1
middle lobe of lung	C34.2	C78.0-☑	D02.21	D14.31	D38.1	D49.1
overlapping lesion	C34.8-☑	—	—	—	—	—
upper lobe of lung	C34.1-☑	C78.0-☑	D02.2-☑	D14.3-☑	D38.1	D49.1
brow	C44.309	C79.2	D04.39	D23.39	D48.5	D49.2
basal cell carcinoma	C44.319	—	—	—	—	—
specified type NEC	C44.399	—	—	—	—	—
squamous cell carcinoma	C44.329	—	—	—	—	—
buccal (cavity)	C06.9	C79.89	D00.00	D10.39	D37.09	D49.0
commissure	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
groove (lower) (upper)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
mucosa	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
sulcus (lower) (upper)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
bulbourethral gland	C68.0	C79.19	D09.19	D30.4	D41.3	D49.59
bursa — *see* Neoplasm, connective tissue						
buttock NEC	C76.3	C79.89	D04.5	D36.7	D48.7	D49.89
calf	C76.5-☑	C79.89	D04.7-☑	D36.7	D48.7	D49.89
calvarium	C41.0	C79.51	—	D16.4	D48.0	D49.2
calyx, renal	C65.-☑	C79.0-☑	D09.19	D30.1-☑	D41.1-☑	D49.51-☑
canal anal	C21.1	C78.5	D01.3	D12.9	D37.8	D49.0
auditory (external) — *see also* Neoplasm, skin, ear	C44.20-☑	C79.2	D04.2-☑	D23.2-☑	D48.5	D49.2
auricular (external) — *see also* Neoplasm, skin, ear	C44.20-☑	C79.2	D04.2-☑	D23.2-☑	D48.5	D49.2
canaliculi, biliary (biliferi) (intrahepatic)	C22.1	C78.7	D01.5	D13.4	D37.6	D49.0
canthus (eye) (inner) (outer)	C44.10-☑	C79.2	D04.1-☑	D23.1-☑	D48.5	D49.2
basal cell carcinoma	C44.11-☑	—	—	—	—	—
sebaceous cell	C44.13-☑	—	—	—	—	—
specified type NEC	C44.19-☑	—	—	—	—	—
squamous cell carcinoma	C44.12-☑	—	—	—	—	—
capillary — *see* Neoplasm, connective tissue						
caput coli	C18.0	C78.5	D01.0	D12.0	D37.4	D49.0
carcinoid — *see* Tumor, carcinoid						
cardia (gastric)	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
cardiac orifice (stomach)	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
cardio-esophageal junction	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
cardio-esophagus	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
carina (bronchus)	C34.0-☑	C78.0-☑	D02.2-☑	D14.3-☑	D38.1	D49.1
carotid (artery)	C49.0	C79.89	—	D21.0	D48.1☑	D49.2
body	C75.4	C79.89	—	D35.5	D44.6	D49.7
carpus (any bone)	C40.1-☑	C79.51	—	D16.1-☑	—	—
cartilage (articular) (joint) NEC — *see also* Neoplasm, bone	C41.9	C79.51	—	D16.9	D48.0	D49.2
arytenoid	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
auricular	C49.0	C79.89	—	D21.0	D48.1☑	D49.2
bronchi	C34.0-☑	C78.39	—	D14.3-☑	D38.1	D49.1
costal	C41.3	C79.51	—	D16.7	D48.0	D49.2
cricoid	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
cuneiform	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
ear (external)	C49.0	C79.89	—	D21.0	D48.1☑	D49.2
ensiform	C41.3	C79.51	—	D16.7	D48.0	D49.2
epiglottis	C32.1	C78.39	D02.0	D14.1	D38.0	D49.1

Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under-dosing
Androstalone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6
Androstanolone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6
Androsterone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6
Anemone pulsatilla	T62.2X1	T62.2X2	T62.2X3	T62.2X4	—	—
Anesthesia						
caudal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
endotracheal	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6
epidural	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
inhalation	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
mucosal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
muscle relaxation	T48.1X1	T48.1X2	T48.1X3	T48.1X4	T48.1X5	T48.1X6
nerve blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
plexus blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
potentiated	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
regional	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
surface	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
Anesthetic NEC — *see also* Anesthesia	T41.41	T41.42	T41.43	T41.44	T41.45	T41.46
with muscle relaxant	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
gaseous NEC	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6
general NEC	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206
halogenated hydrocarbon derivatives NEC	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6
infiltration NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
intravenous NEC	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6
local NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
regional NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
spinal NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
thiobarbiturate	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6
topical	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6
Aneurine	T45.2X1	T45.2X2	T45.2X3	T45.2X4	T45.2X5	T45.2X6
Angeliq*	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6
Angio-Conray	T50.8X1	T50.8X2	T50.8X3	T50.8X4	T50.8X5	T50.8X6
Angiotensin	T44.5X1	T44.5X2	T44.5X3	T44.5X4	T44.5X5	T44.5X6
Angiotensinamide	T44.991	T44.992	T44.993	T44.994	T44.995	T44.996
Anhydrohydroxy-progesterone	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6
Anhydron	T50.2X1	T50.2X2	T50.2X3	T50.2X4	T50.2X5	T50.2X6
Anileridine	T40.491	T40.492	T40.493	T40.494	T40.495	T40.496
Aniline (dye) (liquid)	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—
analgesic	T39.1X1	T39.1X2	T39.1X3	T39.1X4	T39.1X5	T39.1X6
derivatives, therapeutic NEC	T39.1X1	T39.1X2	T39.1X3	T39.1X4	T39.1X5	T39.1X6
vapor	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—
Aniscoropine	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6
Anise oil	T47.5X1	T47.5X2	T47.5X3	T47.5X4	T47.5X5	T47.5X6
Anisidine	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—
Anisindione	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516
Anisotropine methyl-bromide	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6
Anistreplase	T45.611	T45.612	T45.613	T45.614	T45.615	T45.616
Anorexiant (central)	T50.5X1	T50.5X2	T50.5X3	T50.5X4	T50.5X5	T50.5X6
Anorexic agents	T50.5X1	T50.5X2	T50.5X3	T50.5X4	T50.5X5	T50.5X6
Ansaid*	T39.311	T39.312	T39.313	T39.314	T39.315	T39.316
Ansamycin	T36.6X1	T36.6X2	T36.6X3	T36.6X4	T36.6X5	T36.6X6
Ant (bite) (sting)	T63.421	T63.422	T63.423	T63.424	—	—
Antabuse	T50.6X1	T50.6X2	T50.6X3	T50.6X4	T50.6X5	T50.6X6
Antacid NEC	T47.1X1	T47.1X2	T47.1X3	T47.1X4	T47.1X5	T47.1X6
Antagonist						
Aldosterone	T50.0X1	T50.0X2	T50.0X3	T50.0X4	T50.0X5	T50.0X6
alpha-adrenoreceptor	T44.6X1	T44.6X2	T44.6X3	T44.6X4	T44.6X5	T44.6X6
anticoagulant	T45.7X1	T45.7X2	T45.7X3	T45.7X4	T45.7X5	T45.7X6
beta-adrenoreceptor	T44.7X1	T44.7X2	T44.7X3	T44.7X4	T44.7X5	T44.7X6
extrapyramidal NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6
folic acid	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
H2 receptor	T47.0X1	T47.0X2	T47.0X3	T47.0X4	T47.0X5	T47.0X6
heavy metal	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6
narcotic analgesic	T50.7X1	T50.7X2	T50.7X3	T50.7X4	T50.7X5	T50.7X6
opiate	T50.7X1	T50.7X2	T50.7X3	T50.7X4	T50.7X5	T50.7X6
pyrimidine	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
serotonin	T46.5X1	T46.5X2	T46.5X3	T46.5X4	T46.5X5	T46.5X6
Antazolin (e)	T45.0X1	T45.0X2	T45.0X3	T45.0X4	T45.0X5	T45.0X6
Anterior pituitary hormone NEC	T38.811	T38.812	T38.813	T38.814	T38.815	T38.816
Anthelmintic NEC	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6
Anthiolimine	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6
Anthralin	T49.4X1	T49.4X2	T49.4X3	T49.4X4	T49.4X5	T49.4X6
Anthramycin	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
Antiadrenergic NEC	T44.8X1	T44.8X2	T44.8X3	T44.8X4	T44.8X5	T44.8X6
Antiallergic NEC	T45.0X1	T45.0X2	T45.0X3	T45.0X4	T45.0X5	T45.0X6
Antiandrogen NEC	T38.6X1	T38.6X2	T38.6X3	T38.6X4	T38.6X5	T38.6X6
Anti-anemic (drug) (preparation)	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6
Antianxiety drug NEC	T43.501	T43.502	T43.503	T43.504	T43.505	T43.506
Antiaris toxicaria	T65.891	T65.892	T65.893	T65.894	—	—
Antiarteriosclerotic drug	T46.6X1	T46.6X2	T46.6X3	T46.6X4	T46.6X5	T46.6X6
Antiasthmatic drug NEC	T48.6X1	T48.6X2	T48.6X3	T48.6X4	T48.6X5	T48.6X6
Antibiotic Otic Suspension (Solution)*	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
Antibiotic NEC	T36.91	T36.92	T36.93	T36.94	T36.95	T36.96
aminoglycoside	T36.5X1	T36.5X2	T36.5X3	T36.5X4	T36.5X5	T36.5X6
anticancer	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
antifungal	T36.7X1	T36.7X2	T36.7X3	T36.7X4	T36.7X5	T36.7X6
antimycobacterial	T36.5X1	T36.5X2	T36.5X3	T36.5X4	T36.5X5	T36.5X6
antineoplastic	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
b-lactam NEC	T36.1X1	T36.1X2	T36.1X3	T36.1X4	T36.1X5	T36.1X6
cephalosporin (group)	T36.1X1	T36.1X2	T36.1X3	T36.1X4	T36.1X5	T36.1X6
chloramphenicol (group)	T36.2X1	T36.2X2	T36.2X3	T36.2X4	T36.2X5	T36.2X6
ENT	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
eye	T49.5X1	T49.5X2	T49.5X3	T49.5X4	T49.5X5	T49.5X6
fungicidal (local)	T49.0X1	T49.0X2	T49.0X3	T49.0X4	T49.0X5	T49.0X6
intestinal	T36.8X1	T36.8X2	T36.8X3	T36.8X4	T36.8X5	T36.8X6
local	T49.0X1	T49.0X2	T49.0X3	T49.0X4	T49.0X5	T49.0X6
macrolides	T36.3X1	T36.3X2	T36.3X3	T36.3X4	T36.3X5	T36.3X6
polypeptide	T36.8X1	T36.8X2	T36.8X3	T36.8X4	T36.8X5	T36.8X6
specified NEC	T36.8X1	T36.8X2	T36.8X3	T36.8X4	T36.8X5	T36.8X6
tetracycline (group)	T36.4X1	T36.4X2	T36.4X3	T36.4X4	T36.4X5	T36.4X6
throat	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
Anticancer agents NEC	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
Anticholesterolemic drug NEC	T46.6X1	T46.6X2	T46.6X3	T46.6X4	T46.6X5	T46.6X6
Anticholinergic NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6
Anticholinesterase	T44.0X1	T44.0X2	T44.0X3	T44.0X4	T44.0X5	T44.0X6
organophosphorus	T44.0X1	T44.0X2	T44.0X3	T44.0X4	T44.0X5	T44.0X6
insecticide	T60.0X1	T60.0X2	T60.0X3	T60.0X4	—	—
nerve gas	T59.891	T59.892	T59.893	T59.894	—	—
reversible	T44.0X1	T44.0X2	T44.0X3	T44.0X4	T44.0X5	T44.0X6
ophthalmological	T49.5X1	T49.5X2	T49.5X3	T49.5X4	T49.5X5	T49.5X6
Anticoagulant NEC	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516
Antagonist	T45.7X1	T45.7X2	T45.7X3	T45.7X4	T45.7X5	T45.7X6
Anti-common-cold drug NEC	T48.5X1	T48.5X2	T48.5X3	T48.5X4	T48.5X5	T48.5X6
Anticonvulsant	T42.71	T42.72	T42.73	T42.74	T42.75	T42.76
barbiturate	T42.3X1	T42.3X2	T42.3X3	T42.3X4	T42.3X5	T42.3X6
combination (with barbiturate)	T42.3X1	T42.3X2	T42.3X3	T42.3X4	T42.3X5	T42.3X6
hydantoin	T42.0X1	T42.0X2	T42.0X3	T42.0X4	T42.0X5	T42.0X6
hypnotic NEC	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
oxazolidinedione	T42.2X1	T42.2X2	T42.2X3	T42.2X4	T42.2X5	T42.2X6
pyrimidinedione	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
specified NEC	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
succinimide	T42.2X1	T42.2X2	T42.2X3	T42.2X4	T42.2X5	T42.2X6
Antidepressant	T43.201	T43.202	T43.203	T43.204	T43.205	T43.206
monoamine oxidase inhibitor	T43.1X1	T43.1X2	T43.1X3	T43.1X4	T43.1X5	T43.1X6
selective serotonin norepinephrine reuptake inhibitor	T43.211	T43.212	T43.213	T43.214	T43.215	T43.216
selective serotonin reuptake inhibitor	T43.221	T43.222	T43.223	T43.224	T43.225	T43.226
specified NEC	T43.291	T43.292	T43.293	T43.294	T43.295	T43.296
tetracyclic	T43.021	T43.022	T43.023	T43.024	T43.025	T43.026
triazolopyridine	T43.211	T43.212	T43.213	T43.214	T43.215	T43.216
tricyclic	T43.011	T43.012	T43.013	T43.014	T43.015	T43.016
Antidiabetic NEC	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
biguanide	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
and sulfonyl combined	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
combined	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
sulfonylurea	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
Antidiarrheal drug NEC	T47.6X1	T47.6X2	T47.6X3	T47.6X4	T47.6X5	T47.6X6
absorbent	T47.6X1	T47.6X2	T47.6X3	T47.6X4	T47.6X5	T47.6X6
Anti-D immunoglobulin (human)	T50.Z11	T50.Z12	T50.Z13	T50.Z14	T50.Z15	T50.Z16
Antidiphtheria serum	T50.Z11	T50.Z12	T50.Z13	T50.Z14	T50.Z15	T50.Z16
Antidiuretic hormone	T38.891	T38.892	T38.893	T38.894	T38.895	T38.896
Antidote NEC	T50.6X1	T50.6X2	T50.6X3	T50.6X4	T50.6X5	T50.6X6
heavy metal	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6
Antidysrhythmic NEC	T46.2X1	T46.2X2	T46.2X3	T46.2X4	T46.2X5	T46.2X6

Chapter 2. Neoplasms (C00–D49)

Chapter-specific Guidelines with Coding Examples

The chapter-specific guidelines from the ICD-10-CM Official Guidelines for Coding and Reporting have been provided below. Along with these guidelines are coding examples, contained in the shaded boxes, that have been developed to help illustrate the coding and/or sequencing guidance found in these guidelines.

General guidelines

Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms, such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary (metastatic) sites should also be determined.

Primary malignant neoplasms overlapping site boundaries

A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.

A 73-year-old white female with a large rapidly growing malignant tumor in the left breast extending from the upper outer quadrant into the axillary tail

C50.812 **Malignant neoplasm of overlapping sites of left female breast**

Explanation: Because this is a single large tumor that overlaps two contiguous sites, a single code for overlapping sites is assigned.

A 52-year old white female with two distinct lesions of the right breast, one (0.5 cm) in the upper outer quadrant and a second (1.5 cm) in the lower outer quadrant; path report indicates both lesions are malignant

C50.411 **Malignant neoplasm of upper-outer quadrant of right female breast**

C50.511 **Malignant neoplasm of lower-outer quadrant of right female breast**

Explanation: This patient has two distinct malignant lesions of right breast in adjacent quadrants. Because the lesions are not contiguous, two codes are reported.

Malignant neoplasm of ectopic tissue

Malignant neoplasms of ectopic tissue are to be coded to the site of origin mentioned, e.g., ectopic pancreatic malignant neoplasms involving the stomach are coded to malignant neoplasm of pancreas, unspecified (C25.9).

The neoplasm table in the Alphabetic Index should be referenced first. However, if the histological term is documented, that term should be referenced first, rather than going immediately to the Neoplasm Table, in order to determine which column in the Neoplasm Table is appropriate. For example, if the documentation indicates "adenoma," refer to the term in the Alphabetic Index to review the entries under this term and the instructional note to "see also neoplasm, by site, benign." The table provides the proper code based on the type of neoplasm and the site. It is important to select the proper column in the table that corresponds to the type of neoplasm. The Tabular List should then be referenced to verify that the correct code has been selected from the table and that a more specific site code does not exist.

See Section I.C.21. Factors influencing health status and contact with health services, Status, for information regarding Z15.0, codes for genetic susceptibility to cancer.

a. Admission/Encounter for treatment of primary site

If the malignancy is chiefly responsible for occasioning the patient admission/encounter and treatment is directed at the primary site, designate the primary malignancy as the principal/first-listed diagnosis.

The only exception to this guideline is if the administration of chemotherapy, immunotherapy or external beam radiation therapy is chiefly responsible for occasioning the admission/encounter. In that case, assign the appropriate Z51.-- code as the first-listed or principal diagnosis, and the underlying diagnosis or problem for which the service is being performed as a secondary diagnosis.

b. Admission/Encounter for treatment of secondary site

When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only, the secondary neoplasm is designated as the principal diagnosis even though the primary malignancy is still present.

Patient with primary prostate cancer with metastasis to lungs admitted for wedge resection of mass in right lung

C78.01 **Secondary malignant neoplasm of right lung**

C61 **Malignant neoplasm of prostate**

Explanation: Since the admission is for treatment of the lung metastasis, the secondary lung metastasis is sequenced before the primary prostate cancer.

c. Coding and sequencing of complications

Coding and sequencing of complications associated with the malignancies or with the therapy thereof are subject to the following guidelines:

1) Anemia associated with malignancy

When admission/encounter is for management of an anemia associated with the malignancy, and the treatment is only for anemia, the appropriate code for the malignancy is sequenced as the principal or first-listed diagnosis followed by the appropriate code for the anemia (such as code D63.0, Anemia in neoplastic disease).

Patient is admitted for treatment of anemia in advanced colon cancer

C18.9 **Malignant neoplasm of colon, unspecified**

D63.0 **Anemia in neoplastic disease**

Explanation: Even though the admission was solely to treat the anemia, this guideline indicates that the code for the malignancy is sequenced first.

2) Anemia associated with chemotherapy, immunotherapy and radiation therapy

When the admission/encounter is for management of an anemia associated with an adverse effect of the administration of chemotherapy or immunotherapy and the only treatment is for the anemia, the anemia code is sequenced first followed by the appropriate codes for the neoplasm and the adverse effect (T45.1X5, Adverse effect of antineoplastic and immunosuppressive drugs).

A 56-year-old Hispanic male with grade II follicular lymphoma involving multiple lymph node sites referred for blood transfusion to treat anemia due to chemotherapy

D64.81 **Anemia due to antineoplastic chemotherapy**

C82.18 **Follicular lymphoma grade II, lymph nodes of multiple sites**

T45.1X5A **Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter**

Explanation: The code for the anemia is sequenced first followed by the code for the malignant neoplasm and lastly the code for the adverse effect.

When the admission/encounter is for management of an anemia associated with an adverse effect of radiotherapy, the anemia code should be sequenced first, followed by the appropriate neoplasm code and code Y84.2, Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure.

A 55-year-old male with a large malignant rectal tumor has been receiving external radiation therapy to shrink the tumor prior to planned surgery. He is admitted today for a blood transfusion to treat anemia related to radiation therapy.

D64.89 **Other specified anemias**

C20 **Malignant neoplasm of rectum**

Y84.2 **Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure**

Explanation: The code for the anemia is sequenced first, followed by the code for the malignancy, and lastly the code for the abnormal reaction due to radiotherapy.

I72 Other aneurysm

INCLUDES aneurysm (cirsoid) (false) (ruptured)

EXCLUDES 2 *acquired aneurysm (I77.Ø)*
aneurysm (of) aorta (I71.-)
aneurysm (of) arteriovenous NOS (Q27.3-)
carotid artery dissection (I77.71)
cerebral (nonruptured) aneurysm (I67.1)
coronary aneurysm (I25.4)
coronary artery dissection (I25.42)
dissection of artery NEC (I77.79)
dissection of precerebral artery, congenital (nonruptured) (Q28.1)
heart aneurysm (I25.3)
iliac artery dissection (I77.72)
precerebral artery, congential (nonruptured) (Q28.1)
pulmonary artery aneurysm (I28.1)
renal artery dissection (I77.73)
retinal aneurysm (H35.Ø)
ruptured cerebral aneurysm (I6Ø.7)
varicose aneurysm (I77.Ø)
vertebral artery dissection (I77.74)

AHA: 2016,4Q,28-29

I72.Ø Aneurysm of carotid artery
Aneurysm of common carotid artery
Aneurysm of external carotid artery
Aneurysm of internal carotid artery, extracranial portion
EXCLUDES 1 *aneurysm of internal carotid artery, intracranial portion (I67.1)*
aneurysm of internal carotid artery NOS (I67.1)

I72.1 Aneurysm of artery of upper extremity

I72.2 Aneurysm of renal artery

I72.3 Aneurysm of iliac artery

I72.4 Aneurysm of artery of lower extremity
AHA: 2019,2Q,21

I72.5 Aneurysm of other precerebral arteries
Aneurysm of basilar artery (trunk)
EXCLUDES 2 *aneurysm of carotid artery (I72.Ø)*
aneurysm of vertebral artery (I72.6)
dissection of carotid artery (I77.71)
dissection of other precerebral arteries (I77.75)
dissection of vertebral artery (I77.74)

I72.6 Aneurysm of vertebral artery
EXCLUDES 2 *dissection of vertebral artery (I77.74)*

I72.8 Aneurysm of other specified arteries

I72.9 Aneurysm of unspecified site

Aneurysm



I73 Other peripheral vascular diseases

EXCLUDES 2 *chilblains (T69.1)*
frostbite (T33-T34)
immersion hand or foot (T69.Ø-)
spasm of cerebral artery (G45.9)

AHA: 2018,4Q,87

I73.Ø Raynaud's syndrome
Raynaud's disease
Raynaud's phenomenon (secondary)
DEF: Constriction of the arteries of the digits caused by cold or by nerve or arterial damage and can be prompted by stress or emotion. Blood cannot reach the skin and soft tissues and the skin turns white with blue mottling.

I73.ØØ Raynaud's syndrome without gangrene

I73.Ø1 Raynaud's syndrome with gangrene CC HCC

I73.1 Thromboangiitis obliterans [Buerger's disease]
DEF: Inflammatory disease of the extremity blood vessels, mainly the lower blood vessels. This disease is associated with heavy tobacco use. The arteries are more affected than veins. It occurs primarily in young men and leads to tissue ischemia and gangrene.

I73.8 Other specified peripheral vascular diseases
EXCLUDES 1 *diabetic (peripheral) angiopathy (EØ8-E13 with .51-.52)*

I73.81 Erythromelalgia

I73.89 Other specified peripheral vascular diseases
Acrocyanosis
Erythrocyanosis
Simple acroparesthesia [Schultze's type]
Vasomotor acroparesthesia [Nothnagel's type]

I73.9 Peripheral vascular disease, unspecified
Intermittent claudication
Peripheral angiopathy NOS
Spasm of artery
EXCLUDES 1 *atherosclerosis of the extremities (I7Ø.2-I7Ø.7-)*
AHA: 2018,2Q,7

I74 Arterial embolism and thrombosis

INCLUDES embolic infarction
embolic occlusion
thrombotic infarction
thrombotic occlusion

Code first:
embolism and thrombosis complicating abortion or ectopic or molar pregnancy (OØØ-O07, O08.2)
embolism and thrombosis complicating pregnancy, childbirth and the puerperium (O88.-)

EXCLUDES 2 *atheroembolism (I75.-)*
basilar embolism and thrombosis (I63.Ø-I63.2, I65.1)
carotid embolism and thrombosis (I63.Ø-I63.2, I65.2)
cerebral embolism and thrombosis (I63.3-I63.5, I66.-)
coronary embolism and thrombosis (I21-I25)
mesenteric embolism and thrombosis (K55.Ø-)
ophthalmic embolism and thrombosis (H34.-)
precerebral embolism and thrombosis NOS (I63.Ø-I63.2, I65.9)
pulmonary embolism and thrombosis (I26.-)
renal embolism and thrombosis (N28.Ø)
retinal embolism and thrombosis (H34.-)
septic embolism and thrombosis (I76)
vertebral embolism and thrombosis (I63.Ø-I63.2, I65.Ø)

AHA: 2023,2Q,7

I74.Ø Embolism and thrombosis of abdominal aorta

I74.Ø1 Saddle embolus of abdominal aorta MCC HCC

I74.Ø9 Other arterial embolism and thrombosis of abdominal aorta CC HCC
Aortic bifurcation syndrome
Aortoiliac obstruction
Leriche's syndrome

I74.1 Embolism and thrombosis of other and unspecified parts of aorta

I74.1Ø Embolism and thrombosis of unspecified parts of aorta CC HCC

I74.11 Embolism and thrombosis of thoracic aorta CC HCC

I74.19 Embolism and thrombosis of other parts of aorta CC HCC

I74.2 Embolism and thrombosis of arteries of the upper extremities CC HCC

I74.3 Embolism and thrombosis of arteries of the lower extremities CC HCC

I74.4 Embolism and thrombosis of arteries of extremities, unspecified CC HCC
Peripheral arterial embolism NOS

I74.5 Embolism and thrombosis of iliac artery CC HCC

I74.8 Embolism and thrombosis of other arteries CC HCC

I74.9 Embolism and thrombosis of unspecified artery CC HCC

I75 Atheroembolism

INCLUDES atherothrombotic microembolism
cholesterol embolism

I75.Ø Atheroembolism of extremities

I75.Ø1 Atheroembolism of upper extremity

I75.Ø11 Atheroembolism of right upper extremity CC HCC

NØ7.5 Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis CC
Hereditary nephropathy, not elsewhere classified with membranoproliferative glomerulonephritis, types 1 and 3, or NOS
EXCLUDES 1 *hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis (NØ7.A)*
hereditary nephropathy, not elsewhere classified with C3 glomerulopathy (NØ7.A)

NØ7.6 Hereditary nephropathy, not elsewhere classified with dense deposit disease
Hereditary nephropathy, not elsewhere classified with C3 glomerulopathy with dense deposit disease
Hereditary nephropathy, not elsewhere classified with membranoproliferative glomerulonephritis, type 2

NØ7.7 Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis
Hereditary nephropathy, not elsewhere classified with extracapillary glomerulonephritis

NØ7.8 Hereditary nephropathy, not elsewhere classified with other morphologic lesions
Hereditary nephropathy, not elsewhere classified with proliferative glomerulonephritis NOS

NØ7.9 Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions

NØ7.A Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis CC
Hereditary nephropathy, not elsewhere classified with C3 glomerulopathy
EXCLUDES 1 *hereditary nephropathy, not elsewhere classified (with C3 glomerulopathy) with dense deposit disease (NØ7.6)*

NØ8 Glomerular disorders in diseases classified elsewhere
Glomerulonephritis
Nephritis
Nephropathy
Code first underlying disease, such as:
amyloidosis (E85.-)
congenital syphilis (A5Ø.5)
cryoglobulinemia (D89.1)
disseminated intravascular coagulation (D65)
gout (M1A.-, M1Ø.-)
microscopic polyangiitis (M31.7)
multiple myeloma (C9Ø.Ø-)
sepsis (A4Ø.Ø-A41.9)
sickle-cell disease (D57.Ø-D57.8)
EXCLUDES 1 *glomerulonephritis, nephritis and nephropathy (in):*
antiglomerular basement membrane disease (M31.Ø)
diabetes (EØ8-E13 with .21)
gonococcal (A54.21)
Goodpasture's syndrome (M31.Ø)
hemolytic-uremic syndrome (D59.3-)
lupus (M32.14)
mumps (B26.83)
syphilis (A52.75)
systemic lupus erythematosus (M32.14)
Wegener's granulomatosis (M31.31)
pyelonephritis in diseases classified elsewhere (N16)
renal tubulo-interstitial disorders classified elsewhere (N16)

Renal tubulo-interstitial diseases (N1Ø-N16)

INCLUDES pyelonephritis
EXCLUDES 1 *pyeloureteritis cystica (N28.85)*

N1Ø Acute pyelonephritis CC H6
Acute infectious interstitial nephritis
Acute pyelitis
Acute tubulo-interstitial nephritis
Hemoglobin nephrosis
Myoglobin nephrosis
Use additional code (B95-B97), to identify infectious agent
AHA: 2020,3Q,25; 2019,3Q,13

√4th **N11 Chronic tubulo-interstitial nephritis**
INCLUDES chronic infectious interstitial nephritis
chronic pyelitis
chronic pyelonephritis
Use additional code (B95-B97), to identify infectious agent

N11.Ø Nonobstructive reflux-associated chronic pyelonephritis
Pyelonephritis (chronic) associated with (vesicoureteral) reflux
EXCLUDES 1 *vesicoureteral reflux NOS (N13.7Ø)*

N11.1 Chronic obstructive pyelonephritis CC
Pyelonephritis (chronic) associated with anomaly of pelviureteric junction
Pyelonephritis (chronic) associated with anomaly of pyeloureteric junction
Pyelonephritis (chronic) associated with crossing of vessel
Pyelonephritis (chronic) associated with kinking of ureter
Pyelonephritis (chronic) associated with obstruction of ureter
Pyelonephritis (chronic) associated with stricture of pelviureteric junction
Pyelonephritis (chronic) associated with stricture of ureter
EXCLUDES 1 *calculous pyelonephritis (N2Ø.9)*
obstructive uropathy (N13.-)

N11.8 Other chronic tubulo-interstitial nephritis CC
Nonobstructive chronic pyelonephritis NOS

N11.9 Chronic tubulo-interstitial nephritis, unspecified CC H6
Chronic interstitial nephritis NOS
Chronic pyelitis NOS
Chronic pyelonephritis NOS

N12 Tubulo-interstitial nephritis, not specified as acute or chronic CC H6
Interstitial nephritis NOS
Pyelitis NOS
Pyelonephritis NOS
EXCLUDES 1 *calculous pyelonephritis (N2Ø.9)*

√4th **N13 Obstructive and reflux uropathy**
EXCLUDES 2 *calculus of kidney and ureter without hydronephrosis (N2Ø.-)*
congenital obstructive defects of renal pelvis and ureter (Q62.Ø-Q62.3)
hydronephrosis with ureteropelvic junction obstruction (Q62.11)
obstructive pyelonephritis (N11.1)
DEF: Hydronephrosis: Distension of the kidney caused by an accumulation of urine that cannot flow out due to an obstruction that may be caused by conditions such as kidney stones or vesicoureteral reflux.

N13.Ø Hydronephrosis with ureteropelvic junction obstruction CC
Hydronephrosis due to acquired occlusion of ureteropelvic junction
EXCLUDES 2 *hydronephrosis with ureteropelvic junction obstruction due to calculus (N13.2)*
AHA: 2016,4Q,43

Hydronephrosis/UPJ Obstruction



Q18.2 Other branchial cleft malformations PE
Branchial cleft malformation NOS
Cervical auricle
Otocephaly

Q18.3 Webbing of neck PE
Pterygium colli
DEF: Congenital malformation characterized by a thick, triangular skinfold that stretches from the lateral side of the neck across the shoulder. It is associated with genetic conditions such as Turner's and Noonan's syndromes.

Q18.4 Macrostomia PE
DEF: Rare congenital craniofacial bilateral or unilateral anomaly of the mouth due to malformed maxillary and mandibular processes. It results in an abnormally large mouth extending toward the ear.

Q18.5 Microstomia PE

Q18.6 Macrocheilia PE
Hypertrophy of lip, congenital

Q18.7 Microcheilia PE

Q18.8 Other specified congenital malformations of face and neck PE
Medial cyst of face and neck
Medial fistula of face and neck
Medial sinus of face and neck

Q18.9 Congenital malformation of face and neck, unspecified PE
Congenital anomaly NOS of face and neck

Congenital malformations of the circulatory system (Q20-Q28)

Q20 Congenital malformations of cardiac chambers and connections
EXCLUDES 1 *dextrocardia with situs inversus (Q89.3)*
mirror-image atrial arrangement with situs inversus (Q89.3)

Q20.0 Common arterial trunk MCC PE
Persistent truncus arteriosus
EXCLUDES 1 *aortic septal defect (Q21.4)*

Q20.1 Double outlet right ventricle MCC PE
Taussig-Bing syndrome

Q20.2 Double outlet left ventricle MCC PE

Q20.3 Discordant ventriculoarterial connection MCC PE
Dextrotransposition of aorta
Transposition of great vessels (complete)

Q20.4 Double inlet ventricle MCC PE
Common ventricle
Cor triloculare biatriatum
Single ventricle

Q20.5 Discordant atrioventricular connection CC PE
Corrected transposition
Levotransposition
Ventricular inversion

Q20.6 Isomerism of atrial appendages PE
Isomerism of atrial appendages with asplenia or polysplenia

Q20.8 Other congenital malformations of cardiac chambers and connections PE
Cor binoculare

Q20.9 Congenital malformation of cardiac chambers and connections, unspecified PE

Q21 Congenital malformations of cardiac septa
EXCLUDES 1 *acquired cardiac septal defect (I51.Ø)*

Q21.Ø Ventricular septal defect CC PE
Roger's disease

Ventricular Septal Defect



Q21.1 Atrial septal defect
EXCLUDES 2 *ostium primum atrial septal defect (type I) (Q21.2Ø)*
AHA: 2022,4Q,39-40

Atrial Septal Defect



Q21.1Ø Atrial septal defect, unspecified CC PE

Q21.11 Secundum atrial septal defect CC PE
Fenestrated atrial septum
Patent or persistent ostium secundum defect (type II)

Q21.12 Patent foramen ovale CC PE
Persistent foramen ovale

Q21.13 Coronary sinus atrial septal defect CC PE
Coronary sinus defect
Unroofed coronary sinus

Q21.14 Superior sinus venosus atrial septal defect CC PE
Superior vena cava type atrial septal defect

Q21.15 Inferior sinus venosus atrial septal defect CC PE
Inferior vena cava type atrial septal defect

Q21.16 Sinus venosus atrial septal defect, unspecified CC PE
Sinus venosus defect, NOS

Q21.19 Other specified atrial septal defect CC PE
Common atrium
Other specified atrial septal abnormality

√7th **T80.419 Rh incompatibility with hemolytic transfusion reaction, unspecified** CC PE
- Rh incompatibility with hemolytic transfusion reaction at unspecified time after transfusion
- Hemolytic transfusion reaction (HTR) due to Rh incompatibility NOS

√x7th **T80.49 Other Rh incompatibility reaction due to transfusion of blood or blood products** CC PE
- Delayed serologic transfusion reaction (DSTR) from Rh incompatibility
- Other reaction to Rh incompatible blood transfusion

√5th **T80.A Non-ABO incompatibility reaction due to transfusion of blood or blood products**
- Reaction due to incompatibility of minor antigens (Duffy) (Kell) (Kidd) (Lewis) (M) (N) (P) (S)

√x7th **T80.A0 Non-ABO incompatibility reaction due to transfusion of blood or blood products, unspecified** CC PE
- Non-ABO antigen incompatibility reaction from transfusion NOS

√6th **T80.A1 Non-ABO incompatibility with hemolytic transfusion reaction**

√7th **T80.A10 Non-ABO incompatibility with acute hemolytic transfusion reaction** CC PE
- Acute hemolytic transfusion reaction (AHTR) due to non-ABO incompatibility
- Non-ABO incompatibility with hemolytic transfusion reaction less than 24 hours after transfusion

√7th **T80.A11 Non-ABO incompatibility with delayed hemolytic transfusion reaction** CC PE
- Delayed hemolytic transfusion reaction (DHTR) due to non-ABO incompatibility
- Non-ABO incompatibility with hemolytic transfusion reaction 24 or more hours after transfusion

√7th **T80.A19 Non-ABO incompatibility with hemolytic transfusion reaction, unspecified** CC PE
- Hemolytic transfusion reaction (HTR) due to non-ABO incompatibility NOS
- Non-ABO incompatibility with hemolytic transfusion reaction at unspecified time after transfusion

√x7th **T80.A9 Other non-ABO incompatibility reaction due to transfusion of blood or blood products** CC PE
- Delayed serologic transfusion reaction (DSTR) from non-ABO incompatibility
- Other reaction to non-ABO incompatible blood transfusion

√5th **T80.5 Anaphylactic reaction due to serum**
- Allergic shock due to serum
- Anaphylactic shock due to serum
- Anaphylactoid reaction due to serum
- Anaphylaxis due to serum

EXCLUDES 1 *ABO incompatibility reaction due to transfusion of blood or blood products (T80.3-)*
allergic reaction or shock NOS (T78.2)
anaphylactic reaction or shock NOS (T78.2)
anaphylactic reaction or shock due to adverse effect of correct medicinal substance properly administered (T88.6)
other serum reaction (T80.6-)

DEF: Life-threatening hypersensitivity to a foreign serum causing respiratory distress, vascular collapse, and shock.

√x7th **T80.51 Anaphylactic reaction due to administration of blood and blood products** CC PE

√x7th **T80.52 Anaphylactic reaction due to vaccination** CC PE
AHA: 2021,1Q,43

√x7th **T80.59 Anaphylactic reaction due to other serum** CC PE

√5th **T80.6 Other serum reactions**
- Intoxication by serum
- Protein sickness
- Serum rash
- Serum sickness
- Serum urticaria

EXCLUDES 2 *serum hepatitis (B16-B19)*

DEF: Serum sickness: Hypersensitivity to a foreign serum that causes fever, hives, swelling, and lymphadenopathy.

√x7th **T80.61 Other serum reaction due to administration of blood and blood products** CC PE

√x7th **T80.62 Other serum reaction due to vaccination** CC PE
AHA: 2021,1Q,42

√x7th **T80.69 Other serum reaction due to other serum** CC PE
Code also, if applicable, arthropathy in hypersensitivity reactions classified elsewhere (M36.4)

√5th **T80.8 Other complications following infusion, transfusion and therapeutic injection**

√6th **T80.81 Extravasation of vesicant agent**
- Infiltration of vesicant agent

√7th **T80.810 Extravasation of vesicant antineoplastic chemotherapy** CC PE
- Infiltration of vesicant antineoplastic chemotherapy

√7th **T80.818 Extravasation of other vesicant agent** CC PE
- Infiltration of other vesicant agent

√x7th **T80.82 Complication of immune effector cellular therapy** PE
- Complication of chimeric antigen receptor (CAR-T) cell therapy
- Complication of IEC therapy

Use additional code to identify the specific complication, such as:
cytokine release syndrome (D89.83-)
immune effector cell-associated neurotoxicity syndrome (G92.0-)

EXCLUDES 2 ▶*adverse effect of immune checkpoint inhibitors and immunostimulant drugs (T45.AX5)*◀
complication of bone marrow transplant (T86.0)
complication of stem cell transplant (T86.5)

AHA: 2021,4Q,31

√x7th **T80.89 Other complications following infusion, transfusion and therapeutic injection** PE
- Delayed serologic transfusion reaction (DSTR), unspecified incompatibility

Use additional code to identify graft-versus-host reaction, if applicable, (D89.81-)

AHA: 2020,4Q,14

√5th **T80.9 Unspecified complication following infusion, transfusion and therapeutic injection**

√x7th **T80.90 Unspecified complication following infusion and therapeutic injection** PE

√6th **T80.91 Hemolytic transfusion reaction, unspecified incompatibility**

EXCLUDES 1 *ABO incompatibility with hemolytic transfusion reaction (T80.31-)*
non-ABO incompatibility with hemolytic transfusion reaction (T80.A1-)
Rh incompatibility with hemolytic transfusion reaction (T80.41-)

√7th **T80.910 Acute hemolytic transfusion reaction, unspecified incompatibility** CC PE

√7th **T80.911 Delayed hemolytic transfusion reaction, unspecified incompatibility** CC PE

√7th **T80.919 Hemolytic transfusion reaction, unspecified incompatibility, unspecified as acute or delayed** CC PE
- Hemolytic transfusion reaction NOS

√x7th **T80.92 Unspecified transfusion reaction** PE
- Transfusion reaction NOS

Appendix G: Hospital Acquired Conditions

Hospital-acquired conditions (HACs) are conditions considered reasonably preventable through the application of evidence-based guidelines. These conditions, in and of themselves, are either a complication or comorbidity (CC) or major complication or comorbidity (MCC) that as a secondary diagnosis will move the MS-DRG assignment from a lower-paying MS-DRG to a higher-paying MS-DRG. However, if these conditions are not present on admission (meaning they developed during the hospital stay), the CC or MCC designation is nullified and the case will not group to the higher-paying MS-DRG based solely upon the reporting of the HAC code.

HACs are grouped into 14 categories. ICD-10-CM codes in the tabular section of this book that are grouped to one of these HAC categories are identified by an icon specific to that category. As many of these HACs are conditional, this resource provides any additional stipulations that may be required before the code can be considered an HAC. For example, code I26.Ø2 has an HAC indicating it falls in the HAC 10 category for Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) with Total Knee or Hip Replacement. However, I26.Ø2 is not, by itself, a HAC. There must also be a specific ICD-10-PCS code, such as ØSR9Ø19 Replacement of Right Hip Joint with Metal Synthetic Substitute, Cemented, Open Approach, applied in order for I26.Ø2 to act as a HAC.

Note: The resource used to compile this list is based on the proposed, version 42, MS-DRG Grouper software and Definitions Manual files published with the fiscal 2025 IPPS proposed rule. The final, version 42, MS-DRG Grouper files and MS-DRG Definitions Manual files can be found at the following: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/IPPS-Regulations-and-Notices.html.

HAC 01: Foreign Object Retained After Surgery

Secondary diagnosis not POA:

T81.500A
T81.501A
T81.502A
T81.503A
T81.504A
T81.505A
T81.506A
T81.507A
T81.508A
T81.509A
T81.510A
T81.511A
T81.512A
T81.513A
T81.514A
T81.515A
T81.516A
T81.517A
T81.518A
T81.519A
T81.520A
T81.521A
T81.522A
T81.523A
T81.524A
T81.525A
T81.526A
T81.527A
T81.528A
T81.529A
T81.530A
T81.531A
T81.532A
T81.533A
T81.534A
T81.535A
T81.536A
T81.537A
T81.538A
T81.539A
T81.590A
T81.591A
T81.592A
T81.593A
T81.594A
T81.595A
T81.596A
T81.597A
T81.598A
T81.599A
T81.60XA
T81.61XA
T81.69XA

HAC 02: Air Embolism

Secondary diagnosis not POA:

T8Ø.ØXXA

HAC 03: Blood Incompatibility

Secondary diagnosis not POA:

T8Ø.3ØXA
T8Ø.31ØA
T8Ø.311A
T8Ø.319A
T8Ø.39XA

HAC 04: Stage III and IV Pressure Ulcers

Secondary diagnosis not POA:

L89.ØØ3
L89.ØØ4
L89.Ø13
L89.Ø14
L89.Ø23
L89.Ø24
L89.1Ø3
L89.1Ø4
L89.113
L89.114
L89.123
L89.124
L89.133
L89.134
L89.143
L89.144
L89.153
L89.154
L89.2Ø3
L89.2Ø4
L89.213
L89.214
L89.223
L89.224
L89.3Ø3
L89.3Ø4
L89.313
L89.314
L89.323
L89.324
L89.43
L89.44
L89.5Ø3
L89.5Ø4
L89.513
L89.514
L89.523
L89.524
L89.6Ø3
L89.6Ø4
L89.613
L89.614
L89.623
L89.624
L89.813
L89.814
L89.893
L89.894
L89.93
L89.94

HAC 05: Falls and Trauma

Secondary diagnosis not POA:

M99.1Ø
M99.11
M99.18
S02.ØXXA
S02.ØXXB
S02.1Ø1A
S02.1Ø1B
S02.1Ø2A
S02.1Ø2B
S02.1Ø9A
S02.1Ø9B
S02.11ØA
S02.11ØB
S02.111A
S02.111B
S02.112A
S02.112B
S02.113A
S02.113B
S02.118A
S02.118B
S02.119A
S02.119B
S02.11AA
S02.11AB
S02.11BA
S02.11BB
S02.11CA
S02.11CB
S02.11DA
S02.11DB
S02.11EA
S02.11EB
S02.11FA
S02.11FB
S02.11GA
S02.11GB
S02.11HA
S02.11HB
S02.121A
S02.121B
S02.122A
S02.122B
S02.129A
S02.129B
S02.19XA
S02.19XB
S02.2XXB
S02.3ØXA
S02.3ØXB
S02.31XA
S02.31XB
S02.32XA
S02.32XB
S02.4ØØA
S02.4ØØB
S02.4Ø1A
S02.4Ø1B
S02.4Ø2A
S02.4Ø2B
S02.4ØAA
S02.4ØAB
S02.4ØBA
S02.4ØBB
S02.4ØCA
S02.4ØCB
S02.4ØDA
S02.4ØDB
S02.4ØEA
S02.4ØEB
S02.4ØFA
S02.4ØFB
S02.411A
S02.411B
S02.412A
S02.412B
S02.413A
S02.413B
S02.42XA
S02.42XB
S02.6ØØA
S02.6ØØB
S02.6Ø1A
S02.6Ø1B
S02.6Ø2A
S02.6Ø2B
S02.6Ø9A
S02.6Ø9B
S02.61ØA
S02.61ØB
S02.611A
S02.611B
S02.612A
S02.612B
S02.62ØA
S02.62ØB
S02.621A
S02.621B
S02.622A
S02.622B
S02.63ØA
S02.63ØB
S02.631A
S02.631B
S02.632A
S02.632B
S02.64ØA
S02.64ØB
S02.641A
S02.641B
S02.642A
S02.642B
S02.65ØA
S02.65ØB
S02.651A
S02.651B
S02.652A
S02.652B
S02.66XA
S02.66XB
S02.67ØA
S02.67ØB
S02.671A
S02.671B
S02.672A
S02.672B
S02.69XA
S02.69XB
S02.8ØXA
S02.8ØXB
S02.81XA
S02.81XB
S02.82XA
S02.82XB
S02.831A
S02.831B
S02.832A
S02.832B
S02.839A
S02.839B
S02.841A
S02.841B
S02.842A
S02.842B
S02.849A
S02.849B
S02.85XA
S02.85XB
S02.91XA
S02.91XB
S02.92XA
S02.92XB
S06.ØX1A
S06.ØX9A
S06.ØXAA
S06.1X1A
S06.1X2A
S06.1X3A
S06.1X4A
S06.1X5A
S06.1X6A
S06.1X7A
S06.1X8A
S06.1X9A
S06.1XAA
S06.2X1A
S06.2X2A
S06.2X3A
S06.2X4A
S06.2X5A
S06.2X6A
S06.2X7A
S06.2X8A
S06.2X9A
S06.2XAA
S06.3Ø1A
S06.3Ø2A
S06.3Ø3A
S06.3Ø4A
S06.3Ø5A
S06.3Ø6A
S06.3Ø7A
S06.3Ø8A
S06.3Ø9A
S06.3ØAA
S06.31ØA
S06.311A
S06.312A
S06.313A
S06.314A
S06.315A
S06.316A
S06.317A
S06.318A
S06.319A
S06.31AA
S06.32ØA
S06.321A
S06.322A
S06.323A
S06.324A
S06.325A
S06.326A
S06.327A
S06.328A
S06.329A
S06.32AA
S06.33ØA
S06.331A
S06.332A
S06.333A
S06.334A
S06.335A
S06.336A
S06.337A
S06.338A
S06.339A
S06.33AA
S06.34ØA
S06.341A
S06.342A
S06.343A
S06.344A
S06.345A
S06.346A
S06.347A
S06.348A
S06.349A
S06.34AA
S06.35ØA
S06.351A
S06.352A
S06.353A
S06.354A
S06.355A
S06.356A
S06.357A
S06.358A
S06.359A
S06.35AA
S06.36ØA
S06.361A
S06.362A
S06.363A
S06.364A
S06.365A
S06.366A
S06.367A
S06.368A
S06.369A
S06.36AA
S06.37ØA
S06.371A
S06.372A
S06.373A
S06.374A
S06.375A
S06.376A
S06.377A
S06.378A
S06.379A
S06.37AA
S06.38ØA
S06.381A
S06.382A
S06.383A
S06.384A
S06.385A
S06.386A
S06.387A
S06.388A
S06.389A
S06.38AA
S06.4X0A
S06.4X1A
S06.4X2A
S06.4X3A
S06.4X4A
S06.4X5A
S06.4X6A
S06.4X7A
S06.4X8A
S06.4X9A
S06.4XAA
S06.5X0A
S06.5X1A
S06.5X2A
S06.5X3A
S06.5X4A
S06.5X5A
S06.5X6A
S06.5X7A
S06.5X8A
S06.5X9A
S06.5XAA
S06.6X0A
S06.6X1A
S06.6X2A
S06.6X3A
S06.6X4A
S06.6X5A
S06.6X6A
S06.6X7A
S06.6X8A
S06.6X9A
S06.6XAA
S06.811A
S06.812A
S06.813A
S06.814A
S06.815A
S06.816A
S06.817A
S06.818A
S06.819A
S06.81AA
S06.821A
S06.822A
S06.823A
S06.824A
S06.825A
S06.826A
S06.827A
S06.828A
S06.829A
S06.82AA
S06.891A
S06.892A
S06.893A
S06.894A
S06.895A
S06.896A
S06.897A
S06.898A
S06.899A
S06.89AA
S06.8A0A
S06.8A1A
S06.8A2A
S06.8A3A
S06.8A4A
S06.8A5A
S06.8A6A
S06.8A7A
S06.8A8A
S06.8A9A
S06.8AAA
S06.9X1A
S06.9X2A
S06.9X3A
S06.9X4A
S06.9X5A
S06.9X6A
S06.9X7A
S06.9X8A
S06.9X9A
S06.9XAA
S07.ØXXA
S07.1XXA
S07.8XXA
S07.9XXA
S12.ØØØA
S12.ØØØB
S12.ØØ1A
S12.ØØ1B
S12.Ø1XA
S12.Ø1XB
S12.Ø2XA
S12.Ø2XB
S12.Ø3ØA
S12.Ø3ØB
S12.Ø31A
S12.Ø31B
S12.ØØAA
S12.ØØAB
S12.ØØBA
S12.ØØBB
S12.ØØCA
S12.ØØCB
S12.ØØDA
S12.ØØDB
S12.ØØEA
S12.ØØEB
S12.ØØFA
S12.ØØFB
S12.ØØGA
S12.ØØGB
S12.ØØHA
S12.ØØHB
S12.ØØJA
S12.ØØJB
S12.ØØKA
S12.ØØKB
S12.ØØLA
S12.ØØLB
S12.ØØMA
S12.ØØMB
S12.ØØNA
S12.ØØNB
S12.ØØPA
S12.ØØPB
S12.ØØQA
S12.ØØQB
S12.ØØRA
S12.ØØRB
S12.ØØSA
S12.ØØSB
S12.ØØTA
S12.ØØTB
S12.ØØUA
S12.ØØUB
S12.ØØVA
S12.ØØVB
S12.ØØWA
S12.ØØWB
S12.ØØXA
S12.ØØXB
S12.ØØYA
S12.ØØYB
S12.ØØZA
S12.ØØZB
S12.Ø91A
S12.Ø91B
S12.100A
S12.100B
S12.101A
S12.101B
S12.110A
S12.110B
S12.111A
S12.111B
S12.112A
S12.112B
S12.120A
S12.120B
S12.121A
S12.121B
S12.130A
S12.130B
S12.131A
S12.131B
S12.14XA
S12.14XB
S12.150A
S12.150B
S12.151A
S12.151B
S12.190A
S12.190B
S12.191A
S12.191B
S12.200A
S12.200B
S12.201A
S12.201B
S12.230A
S12.230B
S12.231A
S12.231B
S12.24XA
S12.24XB
S12.250A
S12.250B
S12.251A
S12.251B
S12.290A
S12.290B
S12.291A
S12.291B
S12.300A
S12.300B
S12.301A
S12.301B
S12.330A
S12.330B
S12.331A
S12.331B
S12.34XA
S12.34XB
S12.350A
S12.350B
S12.351A
S12.351B
S12.390A
S12.390B
S12.391A
S12.391B
S12.400A
S12.400B
S12.401A
S12.401B
S12.430A
S12.430B
S12.431A
S12.431B
S12.44XA
S12.44XB
S12.450A
S12.450B
S12.451A
S12.451B
S12.490A
S12.490B
S12.491A
S12.491B
S12.500A
S12.500B
S12.501A
S12.501B
S12.530A
S12.530B
S12.531A

Chapter 9. Diseases of the Circulatory System (I00–I99)

Anatomy of the Heart



Heart Cross Section